CMS modified NCD 177 governing Medicare MRI coverage, effective March 7, 2026. Here's what billing teams need to know.
The Centers for Medicare & Medicaid Services updated National Coverage Determination NCD 177, which governs Medicare MRI coverage across all applicable benefit categories. This modification covers MRI and Magnetic Resonance Angiography (MRA) — including contrast-enhanced MRA (CE-MRA), phase contrast (PC) MRA, and time-of-flight (TOF) MRA techniques. The policy does not list specific CPT codes within the NCD document itself, which means your billing team needs to cross-reference your MAC's local coverage determinations to identify applicable codes for claim submission.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Magnetic Resonance Imaging — NCD 177 |
| Policy Code | NCD 177 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | High — MRI is one of the most frequently billed diagnostic imaging services under Medicare |
| Specialties Affected | Radiology, Neurology, Orthopedics, Cardiology, Oncology, Vascular Surgery, Outpatient Hospital |
| Key Action | Review your MAC's LCD for MRI/MRA billing guidelines and audit open claims against the updated NCD 177 criteria before submitting |
CMS MRI Coverage Criteria and Medical Necessity Requirements 2026
The CMS MRI coverage policy under NCD 177 covers MRI as a diagnostic imaging modality for a wide range of soft-tissue lesions and clinical indications. Medical necessity is the central test. CMS recognizes MRI's clinical utility for detecting disruptive, neoplastic, degenerative, and inflammatory lesions across multiple body regions.
MRA — as an application of MRI — is also covered when medical necessity criteria are met. This includes standard MRA techniques like phase contrast and time-of-flight, as well as contrast-enhanced MRA using gadolinium-based contrast agents. CE-MRA applies specifically to blood vessel imaging and blood flow quantification when intravenous gadolinium contrast is administered.
The NCD 177 Medicare framework also distinguishes between diagnostic contexts. MRI is covered for soft-tissue evaluation where it equals or exceeds CT scanning in contrast resolution. The absence of ionizing radiation and the ability to produce multiplanar images — including sagittal and coronal planes — support medical necessity arguments for MRI over alternative modalities in many clinical situations.
One thing billing teams should understand clearly: this coverage policy operates at the national level. Your Medicare Administrative Contractor fills in the gaps. MAC-level local coverage determinations govern the specific codes, diagnoses, and documentation requirements in your region. Don't assume NCD 177 alone tells you everything you need to support a claim.
If your practice bills MRI frequently, prior authorization requirements vary by plan and setting. Medicare fee-for-service generally does not require prior auth for MRI under NCD 177, but Medicare Advantage plans do. Verify prior authorization requirements separately for each payer and plan type in your payer mix.
CMS MRI Exclusions and Non-Covered Indications
NCD 177 does not enumerate a specific list of excluded indications in the policy summary available at the time of this update. However, the general Medicare medical necessity standard applies: MRI claims without adequate documentation of clinical necessity are subject to claim denial.
Several scenarios consistently generate denials under MRI billing. Routine screening MRI without a documented clinical indication is not covered. MRI ordered without supporting documentation of a condition for which imaging is clinically warranted will fail medical necessity review. Repeat imaging without documented clinical change or new indication is another common denial trigger.
The policy also implicitly limits coverage through its clinical framing. MRI is covered when used to detect soft-tissue lesions — disruptive, neoplastic, degenerative, or inflammatory. Imaging that falls outside that clinical rationale needs stronger documentation to survive a review. If you're in a specialty that uses MRI for monitoring rather than initial diagnosis, build that medical necessity argument explicitly into your documentation.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Soft-tissue lesion detection (neoplastic, degenerative, inflammatory, disruptive) | Covered | See MAC LCD for CPT codes | Medical necessity documentation required |
| MRA — phase contrast (PC) technique | Covered | See MAC LCD | Blood flow measurement, venous and arterial |
| MRA — time-of-flight (TOF) technique | Covered | See MAC LCD | Blood vessel structure; indirect blood flow indication |
| Contrast-enhanced MRA (CE-MRA) with gadolinium | Covered | See MAC LCD | IV gadolinium required; better vessel visualization than non-contrast |
| Multiplanar MRI (sagittal, coronal) | Covered | See MAC LCD | Clinical advantage over CT must be documented when relevant |
| MRI with FDA-approved paramagnetic contrast agents | Covered | See MAC LCD | Enhances visualization; must document clinical rationale for contrast use |
| Routine/screening MRI without clinical indication | Not Covered | N/A | No documented medical necessity; consistent claim denial risk |
| MRI without supporting diagnosis documentation | Not Covered | N/A | Medical necessity cannot be established without documentation |
Note: NCD 177 does not list specific CPT or HCPCS codes. All code-level coverage determinations flow through your MAC's local coverage determination.
CMS MRI Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD for MRI/MRA immediately. NCD 177 sets the national standard, but your MAC controls the specific CPT codes and ICD-10 diagnosis requirements for your region. If you don't have the current LCD in hand, request it before March 7, 2026. |
| 2 | Audit your documentation templates against the NCD 177 medical necessity framework. Claims need to reflect the clinical rationale — soft-tissue lesion detection, vascular evaluation, or specific diagnostic need — not just the order. Update your intake and order forms to capture the clinical indication explicitly. |
| 3 | Flag CE-MRA claims for contrast documentation review. Contrast-enhanced MRA requires IV gadolinium. Make sure your charge capture confirms contrast administration and that the ordering documentation supports the clinical need for contrast over non-contrast imaging. |
| 4 | Separate your Medicare Advantage MRI billing workflow from Medicare fee-for-service. NCD 177 governs traditional Medicare. MA plans write their own coverage policy rules. Prior authorization requirements for MRI under MA plans are common and vary widely. Confirm each MA plan's requirements separately. |
| 5 | Review open and pending MRI claims dated close to March 7, 2026. For any MRI claim straddling the effective date, confirm which version of the policy applies and whether your documentation supports the updated criteria. Don't let claims sit in a queue while you wait for clarity. |
| 6 | Train your MRI billing team on MRA technique distinctions. Phase contrast, time-of-flight, and contrast-enhanced MRA are distinct clinical techniques with different documentation requirements. If your coders aren't distinguishing between them, you're at reimbursement risk. |
| 7 | Talk to your compliance officer if you have high MRI volume or complex MRA billing. If MRI reimbursement is a major revenue driver for your practice or facility, the March 7, 2026 effective date is a trigger to schedule a formal policy review. Don't leave that to chance. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for MRI Under NCD 177
A Note on Codes Under NCD 177
NCD 177 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes within the policy document. This is not unusual for a National Coverage Determination — NCDs establish coverage principles and medical necessity standards at a national level. Code-level specificity lives in your MAC's local coverage determination.
This matters for MRI billing because the applicable CPT codes for brain MRI, spine MRI, musculoskeletal MRI, cardiac MRI, and MRA differ significantly across body part and technique. A policy that covers "MRI of soft-tissue lesions" maps to dozens of distinct CPT codes in practice.
What to Do Instead
Contact your Medicare Administrative Contractor and request the current LCD for MRI and MRA services. The LCD will list the specific CPT codes your MAC recognizes, the covered ICD-10-CM diagnosis codes, and any additional documentation or prior authorization requirements.
If your billing software supports policy-to-code mapping, verify that your MRI charge master is aligned with both NCD 177 and your MAC's LCD. A mismatch between those two layers is a claim denial waiting to happen.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.